The Food and Drug Administration has approved a once-monthly treatment for schizophrenia.
Drug maker Otsuka Pharmaceuticals can keep generic versions of its schizophrenia drug off the market, according to published reports.
A generic version of a schizophrenia drug made by Otsuka Holdings and Bristol-Myers Squibb can't be launched until April 2015, according to published reports.
Teva Pharmaceuticals has launched a generic version of a psychiatric drug, the company said Friday.
A new report from the Department of Health and Human Services' Agency for Healthcare Research and Quality found little evidence to support the use of atypical antipsychotic drugs for uses other than those for which they have official approval.
The Food and Drug Administration has approved a psychiatric drug for treating bipolar disorder when used in combination with one of two other drugs.
The U.S. District Court for the District of Delaware has upheld a patent held by...
The drug market for unipolar depression will get smaller over the next decade due to...